

Chapter 28

Graft-Versus-Host Disease

Edward W. Cowen

REFERENCES

1. Gatti RA et al: Immunological reconstitution of sex-linked lymphopenic immunological deficiency. *Lancet* **2**(7583):1366-1369, 1968
2. Laughlin MJ et al: Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia. *N Engl J Med* **351**(22):2265-2275, 2004
3. Loiseau P et al: HLA Association with hematopoietic stem cell transplantation outcome: The number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival. *Biol Blood Marrow Transplant* **13**(8):965-974, 2007
4. Flomenberg N et al: Impact of HLA class I and class II high-resolution matching on outcomes of unrelated donor bone marrow transplantation: HLA-C mismatching is associated with a strong adverse effect on transplantation outcome. *Blood* **104**(7):1923-1930, 2004
5. Lee SJ, Vogelsang G, Flowers ME: Chronic graft-versus-host disease. *Biol Blood Marrow Transplant* **9**(4):215-233, 2003
6. Martin PJ et al: A retrospective analysis of therapy for acute graft-versus-host disease: Initial treatment. *Blood* **76**(8):1464-1472, 1990
7. Flowers MED et al: Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: Long-term follow-up of a randomized trial. *Blood* **100**(2):415-419, 2002
8. Chosidow O et al: Sclerodermatous chronic graft-versus-host disease. Analysis of seven cases. *J Am Acad Dermatol* **26**(1):49-55, 1992
9. Skert C et al: Sclerodermatous chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation: Incidence, predictors and outcome. *Haematologica* **91**(2):258-261, 2006
10. Patel AR et al: The isomorphic response in morphealike chronic graft-vs-host disease. *Arch Dermatol* **144**(9):1229-1231, 2008
11. Billingham RE: The biology of graft-versus-host reactions. *Harvey Lect* **62**:21-78, 1966
12. Bleakley M, Riddell SR: Molecules and mechanisms of the graft-versus-leukaemia effect. *Nat Rev Cancer* **4**(5):371-380, 2004
13. Matzinger P: The danger model: A renewed sense of self. *Science* **296**(5566):301-305, 2002
14. Ferrara JLM et al: Graft-versus-host disease. *The Lancet* **373**(9674):1550-1561, 2009
15. Cavet J et al: Recipient tumor necrosis factor-alpha and interleukin-10 gene polymorphisms associate with early mortality and acute graft-versus-host disease severity in HLA-matched sibling bone marrow transplants. *Blood* **94**(11):3941-3946, 1999
16. Lin MT et al: Genetic variation in the IL-10 pathway modulates severity of acute graft-versus-host disease following hematopoietic cell transplantation: Synergism between IL-10 genotype of patient and IL-10 receptor beta genotype of donor. *Blood* **106**(12):3995-4001, 2005
17. Dickinson AM, Charron D: Non-HLA immunogenetics in hematopoietic stem cell transplantation. *Curr Opin Immunol* **17**(5):517-525, 2005
18. Zeiser R et al: Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. *Blood* **108**(1):390-399, 2006
19. Magenau JM et al: Frequency of CD4(+)/CD25(hi) FOXP3(+) regulatory T cells has diagnostic and prognostic value as a biomarker for acute Graft-versus-Host-Disease. *Biol Blood Marrow Transplant* **16**(7):907-914, 2010
20. Castro-Malaspina H et al: Transplantation in remission improves the disease-free survival of patients with advanced myelodysplastic syndromes treated with myeloablative T cell-depleted stem cell transplants from HLA-identical siblings. *Biol Blood Marrow Transplant* **14**(4):458-468, 2008
21. Schultz K: Pathophysiology of chronic graft-versus-host disease. In: *Chronic Graft versus Host Disease: Interdisciplinary Management*, edited by G Vogelsang, S Pavletic. Cambridge, Cambridge University Press, 2009, pp. 17-30
22. Cutler C et al: Rituximab for steroid-refractory chronic graft-versus-host disease. *Blood* **108**(2):756-762, 2006

23. Zorn E et al: Minor histocompatibility antigen DBY elicits a coordinated B and T cell response after allogeneic stem cell transplantation. *J Exp Med* **199**(8):1133-1142, 2004
24. Miklos DB et al: Antibody responses to H-Y minor histocompatibility antigens correlate with chronic graft-versus-host disease and disease remission. *Blood* **105**(7):2973-2978, 2005
25. Sarantopoulos S et al: Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease. *Blood* **113**(16):3865-3874, 2009
26. Fujii H et al: Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: A report from the Children's Oncology Group. *Blood* **111**(6):3276-3285, 2008
27. Rosenbloom J, Castro SV, Jimenez SA: Narrative review: Fibrotic diseases: Cellular and molecular mechanisms and novel therapies. *Ann Intern Med* **152**(3):159-166, 2010
28. Baroni SS et al: Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. *N Engl J Med* **354**(25):2667-2676, 2006
29. Svegliati S et al: Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. *Blood* **110**(1):237-241, 2007
30. Magro L et al: Imatinib mesylate as salvage therapy for refractory sclerotic chronic graft-versus-host disease. *Blood* **114**(3):719-722, 2009
31. Olivieri A et al: Imatinib for refractory chronic graft-versus-host disease with fibrotic features. *Blood* **114**(3):709-718, 2009
32. Dragun D et al: Stimulatory autoantibodies to platelet-derived growth factor receptors in systemic sclerosis: What functional autoimmunity could learn from receptor biology. *Arthritis Rheum* **60**(4):907-911, 2009
33. Nakasone H et al: Prophylactic impact of imatinib administration after allogeneic stem cell transplantation on the incidence and severity of chronic graft versus host disease in patients with Philadelphia chromosome-positive leukemia. *Leukemia* **24**(6):1236-1239, 2010
34. Seggewiss R et al: Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. *Blood* **105**(6):2473-2479, 2005
35. Mielcarek M et al: Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation. *Blood* **102**(2):756-762, 2003
36. Ohto H et al: Risk of transfusion-associated graft-versus-host disease as a result of directed donations from relatives. *Transfusion* **32**(7):691-693, 1992
37. Ruhl H, Bein G, Sachs UJ: Transfusion-associated graft-versus-host disease. *Transfus Med Rev* **23**(1):62-71, 2009
38. Filipovich AH et al: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. *Biol Blood Marrow Transplant* **11**(12):945-956, 2005
39. Mays SR et al: Approach to the morbilliform eruption in the hematopoietic transplant patient. *Semin Cutan Med Surg* **26**(3):155-162, 2007
40. Hymes SR et al: Cutaneous manifestations of chronic graft-versus-host disease. *Biol Blood Marrow Transplant* **12**(11):1101-1113, 2006
41. Patel AR et al: Rippled skin, fasciitis, and joint contractures. *J Am Acad Dermatol* **59**(6):1070-1074, 2008
42. Bielsa I, Ariza A: Deep morphea. *Semin Cutan Med Surg* **26**(2):90-95, 2007
43. Su WP, Greene SL: Bullous morphea profunda. *Am J Dermatopathol* **8**(2):144-147, 1986
44. Penas PF et al: Sclerodermatous graft-vs-host disease: Clinical and pathological study of 17 patients. *Arch Dermatol* **138**(7):924-934, 2002
45. Schaffer JV et al: Lichen sclerosus and eosinophilic fasciitis as manifestations of chronic graft-versus-host disease: Expanding the sclerodermoid spectrum. *J Am Acad Dermatol* **53**(4):591-601, 2005
46. Alexis AF, Busam K, Myskowski PL: Porokeratosis of Mibelli following bone marrow transplantation. *Int J Dermatol* **45**(4):361-365, 2006
47. Adamski H et al: Eruptive angiomatous lesions associated with graft-versus-host disease. *Br J Dermatol* **149**(3):667-668, 2003
48. Sanli H et al: Hyperkeratosis of the nipple associated with chronic graft versus host disease after allogeneic haematopoietic cell transplantation. *Acta Derm Venereol* **83**(5):385-386, 2003
49. Sanli H et al: Vitiligo after hematopoietic cell transplantation: Six cases and review of the literature. *Dermatology* **216**(4):349-354, 2008
50. Sanli H et al: Simultaneous onset of chronic graft versus host disease and alopecia areata following allogeneic haematopoietic cell transplantation. *Acta Derm Venereol* **84**(1):86-87, 2004

51. Costantini S et al: The management of severe vaginal obstruction from genital chronic graft-versus-host disease: Diagnosis, surgical technique and follow-up. *Minerva Ginecol* **58**(1):11-16, 2006
52. Marra DE, McKee PH, Nghiem P: Tissue eosinophils and the perils of using skin biopsy specimens to distinguish between drug hypersensitivity and cutaneous graft-versus-host disease. *J Am Acad Dermatol* **51**(4):543-546, 2004
53. Weaver J, Bergfeld WF: Quantitative analysis of eosinophils in acute graft-versus-host disease compared with drug hypersensitivity reactions. *Am J Dermatopathol* **32**(1):31-34
54. Nishio N et al: Engraftment syndrome following allogeneic hematopoietic stem cell transplantation in children. *Pediatr Transplant* **13**(7):831-837, 2009
55. Horn TD et al: The significance of oral mucosal and salivary gland pathology after allogeneic bone marrow transplantation. *Arch Dermatol* **131**(8):964-965, 1995
56. Patriarca F et al: The development of autoantibodies after allogeneic stem cell transplantation is related with chronic graft-vs-host disease and immune recovery. *Exp Hematol* **34**(3):389-396, 2006
57. Schultz KR et al: Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. *Biol Blood Marrow Transplant* **12**(2):126-137, 2006
58. Paczesny S et al: Elafin is a biomarker of graft-versus-host disease of the skin. *Sci Transl Med* **2**(13):13ra12, 2010
59. Clark J et al: Magnetic resonance imaging in sclerotic-type chronic graft-vs-host disease. *Arch Dermatol* **145**(8):918-922, 2009
60. Oda K et al: Fasciitis and myositis: An analysis of muscle-related complications caused by chronic GVHD after allo-SCT. *Bone Marrow Transplant* **43**(2):159-167, 2009
61. Curtis RE et al: Solid cancers after bone marrow transplantation. *N Engl J Med* **336**(13):897-904, 1997
62. Leisenring W et al: Nonmelanoma skin and mucosal cancers after hematopoietic cell transplantation. *J Clin Oncol* **24**(7):1119-1126, 2006
63. Cowen EW et al: Chronic phototoxicity and aggressive squamous cell carcinoma of the skin in children and adults during treatment with voriconazole. *J Am Acad Dermatol* **62**(1):31-37, 2010
64. Altman JS, Adler SS: Development of multiple cutaneous squamous cell carcinomas during PUVA treatment for chronic graft-versus-host disease. *J Am Acad Dermatol* **31**(3 Pt 1):505-507, 1994
65. Wingard JR et al: Predictors of death from chronic graft-versus-host disease after bone marrow transplantation. *Blood* **74**(4):1428-1435, 1989
66. Przepiorka D et al: Chronic graft-versus-host disease after allogeneic blood stem cell transplantation. *Blood* **98**(6):1695-1700, 2001
67. Pavletic SZ et al: Prognostic factors of chronic graft-versus-host disease after allogeneic blood stem-cell transplantation. *Am J Hematol* **78**(4):265-274, 2005
68. Arora M et al: Chronic graft-versus-host disease: A prospective cohort study. *Biol Blood Marrow Transplant* **9**(1):38-45, 2003
69. Akpek G et al: Development of a prognostic model for grading chronic graft-versus-host disease. *Blood* **97**(5):1219-1226, 2001
70. Pidala J, Anasetti C: Glucocorticoid-refractory acute graft vs. Host disease. *Biol Blood Marrow Transplant* **16**:1504-1518, 2010
71. Wiesmann A et al: Treatment of acute graft-versus-host disease with PUVA (psoralen and ultraviolet irradiation): Results of a pilot study. *Bone Marrow Transplant* **23**(2):151-155, 1999
72. Grundmann-Kollmann M et al: Narrowband UV-B phototherapy in the treatment of cutaneous graft versus host disease. *Transplantation* **74**(11):1631-1634, 2002
73. Wetzig T et al: Medium dose long-wavelength ultraviolet A (UVA1) phototherapy for the treatment of acute and chronic graft-versus-host disease of the skin. *Bone Marrow Transplant* **35**(5):515-519, 2005
74. Levine JE et al: Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. *Blood* **111**(4):2470-2475, 2008
75. Le Blanc K et al: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. *Lancet* **363**(9419):1439-1441, 2004
76. Ringden O et al: Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. *Transplantation* **81**(10):1390-1397, 2006
77. Le Blanc K et al: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: A phase II study. *Lancet* **371**(9624):1579-1586, 2008

78. Selmani Z et al: Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. *Stem Cells* **26**(1):212-222, 2008
79. Wolf D, Wolf AM: Mesenchymal stem cells as cellular immunosuppressants. *Lancet* **371**(9624):1553-1554, 2008
80. Pavletic SZ et al: Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. *Biol Blood Marrow Transplant* **12**(3):252-266, 2006
81. Cowen EW: A call for more dermatologic input into chronic graft-vs-host disease clinical trials. *Arch Dermatol* **145**(3):337-338, 2009
82. Patel AR et al: Voriconazole-induced phototoxicity masquerading as chronic graft-versus-host disease of the skin in allogeneic hematopoietic cell transplant recipients. *Biol Blood Marrow Transplant* **15**(3):370-376, 2009
83. Couriel D et al: Ancillary therapy and supportive care of chronic graft-versus-host disease: National institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. *Biol Blood Marrow Transplant* **12**(4):375-396, 2006
84. Choi CJ, Nghiem P: Tacrolimus ointment in the treatment of chronic cutaneous graft-vs-host disease: A case series of 18 patients. *Arch Dermatol* **137**(9):1202-1206, 2001
85. Elad S et al: Topical tacrolimus—a novel treatment alternative for cutaneous chronic graft-versus-host disease. *Transpl Int* **16**(9):665-670, 2003
86. Schmook T et al: Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus. *Bone Marrow Transplant* **36**(1):87-88, 2005
87. Camus M et al: Hydroquinone is both effective on pigmentation and lichenoid papules of chronic lichenoid graft-versus-host disease. *J Eur Acad Dermatol Venereol* **24**(1):96-97, 2010
88. Vogelsang GB et al: Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). *Bone Marrow Transplant* **17**(6):1061-1067, 1996
89. Leiter U et al: Psoralen plus ultraviolet-A-bath photochemotherapy as an adjunct treatment modality in cutaneous chronic graft versus host disease. *Photodermatol Photoimmunol Photomed* **18**(4):183-190, 2002
90. Brazzelli V et al: Narrowband ultraviolet B phototherapy in the treatment of cutaneous graft-versus-host disease in oncohaematological paediatric patients. *Br J Dermatol* **162**(2):404-409, 2010
91. Enk CD et al: Chronic graft-versus-host disease treated with UVB phototherapy. *Bone Marrow Transplant* **22**(12):1179-1183, 1998
92. Kreuter A et al: Low-dose ultraviolet-A1 phototherapy for lichen sclerosus et atrophicus. *Clin Exp Dermatol* **26**(1):30-32, 2001
93. El-Mofty M et al: Low-dose broad-band UVA in morphea using a new method for evaluation. *Photodermatol Photoimmunol Photomed* **16**(2):43-49, 2000
94. Kerscher M et al: Low-dose UVA phototherapy for treatment of localized scleroderma. *J Am Acad Dermatol* **38**(1):21-26, 1998
95. El-Mofty M et al: Different low doses of broad-band UVA in the treatment of morphea and systemic sclerosis. *Photodermatol Photoimmunol Photomed* **20**(3):148-156, 2004
96. Ziemer M et al: Chronic cutaneous graft-versus-host disease in two children responds to UVA1 therapy: Improvement of skin lesions, joint mobility, and quality of life. *J Am Acad Dermatol* **51**(2):318-319, 2004
97. Stander H, Schiller M, Schwarz T: UVA1 therapy for sclerodermic graft-versus-host disease of the skin. *J Am Acad Dermatol* **46**(5):799-800, 2002
98. Calzavara Pinton P et al: Prospects for ultraviolet A1 phototherapy as a treatment for chronic cutaneous graft-versus-host disease. *Haematologica* **88**(10):1169-1175, 2003
99. Kroft EB et al: Ultraviolet A phototherapy for sclerotic skin diseases: A systematic review. *J Am Acad Dermatol* **59**(6):1017-1030, 2008
100. Couriel DR et al: Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD. *Blood* **107**(8):3074-3080, 2006
101. Romano C et al: Extracorporeal photochemotherapy in the treatment of eosinophilic fasciitis. *J Eur Acad Dermatol Venereol* **17**(1):10-13, 2003
102. Sbano P et al: Extracorporeal photochemotherapy for treatment of fasciitis in chronic graft-versus-host disease. *Bone Marrow Transplant* **33**(8):869-870, 2004
103. Minciullo PL et al: Eosinophilic fasciitis associated with autoimmune phenomena after bone marrow transplantation: Report of two cases. *Clin Rheumatol* **25**(1):80-82, 2006

104. Marcellus DC et al: Etrexinate therapy for refractory sclerodermatous chronic graft-versus-host disease. *Blood* **93**(1):66-70, 1999
105. Ghoreschi K et al: PUVA-bath photochemotherapy and isotretinoin in sclerodermatous graft-versus-host disease. *Eur J Dermatol* **18**(6):667-670, 2008
106. Moreno-Romero JA et al: Imatinib as a potential treatment for sclerodermatous chronic graft-versus-host disease. *Arch Dermatol* **144**(9):1106-1109, 2008
107. Zhou H et al: Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: Clinical report. *Biol Blood Marrow Transplant* **16**(3):403-412, 2010
108. Eckardt A et al: Severe oral chronic graft-versus-host disease following allogeneic bone marrow transplantation: Highly effective treatment with topical tacrolimus. *Oral Oncol* **40**(8):811-814, 2004
109. Conrotto D et al: Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. *Transplantation* **82**(8):1113-1115, 2006
110. Turner ML, Stratton P: Gynecological manifestations of chronic graft versus host disease. In: *Chronic Graft versus Host Disease: Interdisciplinary Management*, edited by G Vogelsang, S Pavletic. Cambridge, Cambridge University Press, 2009, pp. 207-215
111. Przepiorka D et al: 1994 Consensus Conference on Acute GVHD Grading. *Bone Marrow Transplant* **15**(6):825-828, 1995
112. Doney KC et al: Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: A randomized trial comparing antithymocyte globulin and corticosteroids. *Am J Hematol* **11**(1):1-8, 1981
113. Ruutu T et al: A survey of the prophylaxis and treatment of acute GVHD in Europe: A report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. *Bone Marrow Transplant* **19**(8):759-764, 1997
114. Furlong T et al: Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. *Bone Marrow Transplant* **26**(9):985-991, 2000
115. Aschan J: Treatment of moderate to severe acute graft-versus-host disease: A retrospective analysis. *Bone Marrow Transplant* **14**(4):601-607, 1994
116. Pidala J et al: Mycophenolate mofetil for the management of steroid-refractory acute graft vs host disease. *Bone Marrow Transplant* **45**(5):919-924, 2010
117. Baudard M et al: Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: A series of 21 BM or PBSC transplant patients. *Bone Marrow Transplant* **30**(5):287-295, 2002
118. Busca A et al: Recombinant human soluble tumor necrosis factor receptor fusion protein as treatment for steroid refractory graft-versus-host disease following allogeneic hematopoietic stem cell transplantation. *Am J Hematol* **82**(1):45-52, 2007
119. Pidala J et al: Infliximab for managing steroid-refractory acute graft-versus-host disease. *Biol Blood Marrow Transplant* **15**(9):1116-1121, 2009
120. Couriel D et al: Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. *Blood* **104**(3):649-654, 2004
121. Ho VT et al: Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Blood* **104**(4):1224-1226, 2004
122. Bolanos-Meade J et al: Pentostatin in steroid-refractory acute graft-versus-host disease. *J Clin Oncol* **23**(12):2661-2668, 2005
123. Arai S et al: Poor outcome in steroid-refractory graft-versus-host disease with antithymocyte globulin treatment. *Biol Blood Marrow Transplant* **8**(3):155-160, 2002
124. Khoury H et al: Treatment of steroid-resistant acute graft-versus-host disease with antithymocyte globulin. *Bone Marrow Transplant* **27**(10):1059-1064, 2001
125. Greinix HT et al: Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: A pilot study. *Blood* **96**(7):2426-2431, 2000
126. Messina C et al: Extracorporeal photochemotherapy for paediatric patients with graft-versus-host disease after haematopoietic stem cell transplantation. *Br J Haematol* **122**(1):118-127, 2003
127. Shapira MY et al: Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: A preliminary report. *Bone Marrow Transplant* **36**(12):1097-1101, 2005

128. Bordigoni P et al: Daclizumab, an efficient treatment for steroid-refractory acute graft-versus-host disease. *Br J Haematol* **135**(3):382-385, 2006
129. Pinana JL et al: Encouraging results with inolimomab (anti-IL-2 receptor) as treatment for refractory acute graft-versus-host disease. *Biol Blood Marrow Transplant* **12**(11):1135-1141, 2006
130. Funke VA et al: Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist. *Bone Marrow Transplant* **37**(10):961-965, 2006
131. Massenkeil G et al: Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. *Bone Marrow Transplant* **30**(12):899-903, 2002
132. Macmillan ML et al: A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease. *Blood* **109**(6):2657-2662, 2007
133. Carpenter PA et al: A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. *Biol Blood Marrow Transplant* **11**(6):465-471, 2005
134. Gomez-Almaguer D et al: Alemtuzumab for the treatment of steroid-refractory acute graft-versus-host disease. *Biol Blood Marrow Transplant* **14**(1):10-15, 2008
135. Martinez C et al: Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: Results of a phase II study. *Biol Blood Marrow Transplant* **15**(5):639-642, 2009
136. Furlong T et al: Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. *Biol Blood Marrow Transplant* **8**(4):206-212, 2002
137. Wolff D et al: Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): First-line and topical treatment of chronic GVHD. *Biol Blood Marrow Transplant* **17**:1-17, 2011
138. Carnevale-Schianca F et al: Changing from cyclosporine to tacrolimus as salvage therapy for chronic graft-versus-host disease. *Biol Blood Marrow Transplant* **6**(6):613-620, 2000
139. Koc S et al: Therapy for chronic graft-versus-host disease: A randomized trial comparing cyclosporine plus prednisone versus prednisone alone. *Blood* **100**(1):48-51, 2002
140. Seaton ED et al: Influence of extracorporeal photopheresis on clinical and laboratory parameters in chronic graft-versus-host disease and analysis of predictors of response. *Blood* **102**(4):1217-1223, 2003
141. Gilman AL et al: Hydroxychloroquine for the treatment of chronic graft-versus-host disease. *Biol Blood Marrow Transplant* **6**(3A):327-334, 2000
142. Goldberg JD et al: Pentostatin for the treatment of chronic graft-versus-host disease in children. *J Pediatr Hematol Oncol* **25**(7):584-588, 2003
143. Johnston LJ et al: Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. *Biol Blood Marrow Transplant* **11**(1):47-55, 2005
144. Couriel DR et al: Sirolimus in combination with tacrolimus and corticosteroids for the treatment of resistant chronic graft-versus-host disease. *Br J Haematol* **130**(3):409-417, 2005
145. Zaja F et al: Treatment of refractory chronic GVHD with rituximab: A GITMO study. *Bone Marrow Transplant* **40**(3):273-277, 2007
146. Teachey DT, Bickert B, Bunin N: Daclizumab for children with corticosteroid refractory graft-versus-host disease. *Bone Marrow Transplant* **37**(1):95-99, 2006
147. Giaccone L et al: Safety and potential efficacy of low-dose methotrexate for treatment of chronic graft-versus-host disease. *Bone Marrow Transplant* **36**(4):337-341, 2005
148. Huang XJ et al: Low-dose methotrexate for the treatment of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. *Bone Marrow Transplant* **36**(4):343-348, 2005
149. Lee SJ et al: Treatment of chronic graft-versus-host disease with clofazimine. *Blood* **89**(7):2298-2302, 1997
150. Chiang KY et al: Recombinant human tumor necrosis factor receptor fusion protein as complementary treatment for chronic graft-versus-host disease. *Transplantation* **73**(4):665-667, 2002
151. Browne PV et al: Response to thalidomide therapy in refractory chronic graft-versus-host disease. *Bone Marrow Transplant* **26**(8):865-869, 2000
152. Kulkarni S et al: Thalidomide after allogeneic hematopoietic stem cell transplantation: Activity in chronic but not in acute graft-versus-host disease. *Bone Marrow Transplant* **32**(2):165-170, 2003
153. Shapira MY et al: Alefacept treatment for refractory chronic extensive GVHD. *Bone Marrow Transplant* **43**(4):339-343, 2009

154. Robin M et al: Low-dose thoracoabdominal irradiation for the treatment of refractory chronic graft-versus-host disease. *Transplantation* **80**(5):634-642, 2005